Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Pearls collections: What we can learn about infectious disease and cancer.

Knoll LJ, Hogan DA, Leong JM, Heitman J, Condit RC.

PLoS Pathog. 2018 Mar 29;14(3):e1006915. doi: 10.1371/journal.ppat.1006915. eCollection 2018 Mar. No abstract available.

2.

High Initial Sputter Rate Found for Vaccinia Virions Using Isotopic Labeling, NanoSIMS, and AFM.

Gates SD, Condit RC, Moussatche N, Stewart BJ, Malkin AJ, Weber PK.

Anal Chem. 2018 Feb 6;90(3):1613-1620. doi: 10.1021/acs.analchem.7b02786. Epub 2018 Jan 19.

PMID:
29295620
3.

Editorial introduction to "Ranaviruses and other members of the family Iridoviridae: Their place in the virosphere," a special emphasis section of Virology.

Condit RC, Gregory Chinchar V.

Virology. 2017 Nov;511:257-258. doi: 10.1016/j.virol.2017.08.014. Epub 2017 Aug 30. No abstract available.

PMID:
28860048
4.

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.

Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Review.

5.

Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.

Klug B, Robertson JS, Condit RC, Seligman SJ, Laderoute MP, Sheets R, Williamson AL, Gurwith M, Kochhar S, Chapman L, Carbery B, Mac LM, Chen RT; Brighton Collaboration Viral Vaccine Vector Safety Working Group. Electronic address: brightoncollaborationv3swg@gmail.com.

Vaccine. 2016 Dec 12;34(51):6617-6625. doi: 10.1016/j.vaccine.2016.02.015. Epub 2016 Jun 15. Review.

6.

An improved high pressure freezing and freeze substitution method to preserve the labile vaccinia virus nucleocapsid.

Jesus DM, Moussatche N, Condit RC.

J Struct Biol. 2016 Jul;195(1):41-8. doi: 10.1016/j.jsb.2016.05.001. Epub 2016 May 4.

PMID:
27155322
7.

Biochemical analysis of the multifunctional vaccinia mRNA capping enzyme encoded by a temperature sensitive virus mutant.

Tate J, Boldt RL, McFadden BD, D'Costa SM, Lewandowski NM, Shatzer AN, Gollnick P, Condit RC.

Virology. 2016 Jan;487:27-40. doi: 10.1016/j.virol.2015.10.011. Epub 2015 Oct 20.

8.

The vaccinia virus E6 protein influences virion protein localization during virus assembly.

Condit RC, Moussatche N.

Virology. 2015 Aug;482:147-56. doi: 10.1016/j.virol.2015.02.056. Epub 2015 Apr 10.

9.

Vaccinia virus protein A3 is required for the production of normal immature virions and for the encapsidation of the nucleocapsid protein L4.

Jesus DM, Moussatche N, McFadden BB, Nielsen CP, D'Costa SM, Condit RC.

Virology. 2015 Jul;481:1-12. doi: 10.1016/j.virol.2015.02.020. Epub 2015 Mar 9.

10.

Fine structure of the vaccinia virion determined by controlled degradation and immunolocalization.

Moussatche N, Condit RC.

Virology. 2015 Jan 15;475:204-18. doi: 10.1016/j.virol.2014.11.020. Epub 2014 Dec 8.

11.

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Review.

12.

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Chen RT, Carbery B, Mac L, Berns KI, Chapman L, Condit RC, Excler JL, Gurwith M, Hendry M, Khan AS, Khuri-Bulos N, Klug B, Robertson JS, Seligman SJ, Sheets R, Williamson AL; V3SWG.

Vaccine. 2015 Jan 1;33(1):73-5. doi: 10.1016/j.vaccine.2014.09.035. Epub 2014 Oct 8.

13.

Vaccinia virus mutations in the L4R gene encoding a virion structural protein produce abnormal mature particles lacking a nucleocapsid.

Jesus DM, Moussatche N, Condit RC.

J Virol. 2014 Dec;88(24):14017-29. doi: 10.1128/JVI.02126-14. Epub 2014 Sep 24.

14.

Editorial introduction to "Giant Viruses" special issue of Virology.

Fischer MG, Condit RC.

Virology. 2014 Oct;466-467:1-2. doi: 10.1016/j.virol.2014.07.047. Epub 2014 Aug 28. No abstract available.

15.

Biochemical and biophysical properties of a putative hub protein expressed by vaccinia virus.

Kay NE, Bainbridge TW, Condit RC, Bubb MR, Judd RE, Venkatakrishnan B, McKenna R, D'Costa SM.

J Biol Chem. 2013 Apr 19;288(16):11470-81. doi: 10.1074/jbc.M112.442012. Epub 2013 Mar 8.

16.

Vaccinia virions deficient in transcription enzymes lack a nucleocapsid.

McFadden BD, Moussatche N, Kelley K, Kang BH, Condit RC.

Virology. 2012 Dec 5;434(1):50-8. doi: 10.1016/j.virol.2012.08.019. Epub 2012 Sep 1.

17.

Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain.

Cao H, Dai P, Wang W, Li H, Yuan J, Wang F, Fang CM, Pitha PM, Liu J, Condit RC, McFadden G, Merghoub T, Houghton AN, Young JW, Shuman S, Deng L.

PLoS One. 2012;7(5):e36823. doi: 10.1371/journal.pone.0036823. Epub 2012 May 14.

18.

Biological characterization and next-generation genome sequencing of the unclassified Cotia virus SPAn232 (Poxviridae).

Afonso PP, Silva PM, Schnellrath LC, Jesus DM, Hu J, Yang Y, Renne R, Attias M, Condit RC, Moussatché N, Damaso CR.

J Virol. 2012 May;86(9):5039-54. doi: 10.1128/JVI.07162-11. Epub 2012 Feb 15.

19.

Whence feral vaccinia?

Condit RC.

Emerg Infect Dis. 2010 Jun;16(6):1022. doi: 10.3201/eid1606.100315. No abstract available.

20.

Surf and turf: mechanism of enhanced virus spread during poxvirus infection.

Condit RC.

Viruses. 2010 May;2(5):1050-4. doi: 10.3390/v2051050. Epub 2010 Apr 28.

Supplemental Content

Support Center